Navigation Links
Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Date:3/31/2009

cines against diseases endemic to India and the surrounding regions, including hepatitis E, chikungunya fever, dengue fever, and rabies. Hepatitis E is a principal cause of hepatitis among adults under 40 years of age, associated with fulminant hepatitis and a mortality rate of up to 20% in infected pregnant women. Dengue fever is a mosquito-borne disease, which has re-emerged in India. Dengue fever is characterized by severe pain in the eyes, head and extremities. It has a very high mortality rate. There is no vaccine or definitive treatment for Dengue fever currently. In 2006, dengue fever swept through the country and many hospitals were overwhelmed. Rabies is responsible for 25,000 to 30,000 deaths annually in India.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

About Cadila (www.cadilapharma.com)

Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the state of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over fifty countries around the world. Cadila Pharmaceuticals is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... on providing advanced testing solutions for the detection ... for the three months and full year ended ... Financial Results:Revenue for the quarter ended December 31, ... the fourth quarter of 2013 and $1.5 million ...
(Date:3/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... certain matters, including the appointment of auditors, its annual ... 2015 (the "Meeting") was adjourned, as previously disclosed on ... a.m. ( Toronto time). The date ... previous disclosed. The Meeting will reconvene at the offices ...
(Date:3/26/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, announced ... commercial officer. Salyer has more than 20 years of ... sciences. At BioNano, Salyer will oversee the commercialization of ... assemble a comprehensive view of complex genomes to help ... located in the United States , ...
(Date:3/26/2015)... March 26, 2015 Neogen Corporation (NASDAQ: ... the third quarter of fiscal 2015, which ended Feb. ... prior year,s $6,575,000. Earnings per share in the current ... Current year-to-date net income increased 17% over prior year ... or $0.56 per share, for the same period a ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... SpectraScience, Inc. (OTC,Bulletin Board: SCIE), a San Diego based ... of its WavSTAT(R) Optical Biopsy Systems to,the Almeda Company ... at,the University of Prague during colonoscopy to determine if ... for polyps, which are abnormal growths that,stick out from ...
... Storage Systems Fuel Faster Time to Discovery for ... Seeking Causes and Cures of Disease, BOSTON, April 30 ... scientists seek to accelerate sequencing,genomes of varied arrays of organisms ... causes and cures of diseases that plague mankind,breakthrough technology from ...
... --,China Biologic Products, Inc. (OTC Bulletin Board: ... leading plasma-based pharmaceutical companies in the,People,s Republic ... Company,received approval from the Chinese State Food ... production of Cryoprecipitate, or "cryo," a,frozen blood ...
Cached Biology Technology:Sale of Colon Cancer Diagnostic Tool to Czech Republic 2SGI Breakthrough Technology Empowers Genome Center Research Around the World 2SGI Breakthrough Technology Empowers Genome Center Research Around the World 3SGI Breakthrough Technology Empowers Genome Center Research Around the World 4SGI Breakthrough Technology Empowers Genome Center Research Around the World 5China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 2China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 3
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
(Date:3/10/2015)... Colo. , March 10, 2015 ... Flight "Personalized Medicine in Human Space ... and Thomas J. Goodwin , Ph.D. was recently ... of the past two years. Specifically, "Personalized ... most downloaded scientific papers published in 2013 and 2014 ...
(Date:3/10/2015)... Conn. , March 10, 2015  NXT-ID, ... ("NXT-ID" or the "Company"), a biometric authentication company ... the company,s Wocket™ smart wallet has been named ... by Rethink Modern. Rethink Modern ( ... and innovative items for your home and lifestyle that have ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... bears from the Iberian Peninsula are not as genetically different ... An international study being published this week in Proceedings ... the contrary, the Spanish bear was only recently isolated from ... the discussion of how to save the population of Spanish ...
... by the University of Leeds aims to find novel ... leading European experts in membrane proteins. The project ... (EDICT) will target about 80 proteins, which play ... diabetes, heart disease, neuropsychiatric disorders like epilepsy and depression, ...
... 18, 2008 A group of some 15 chimpanzees ... a greater range and, thus, greater chances for survival ... and ecological research efforts ever. Organizers of the project, named ... (50km) tree corridor will be planted to connect the Gishwati ...
Cached Biology News:New study changes conditions for Spanish brown bears 2European membrane expertise to focus on new treatments for human diseases 2Rwanda conservation effort to link isolated chimps to distant forest 2Rwanda conservation effort to link isolated chimps to distant forest 3
... Fully automated microarray slide processing offering ... The trend to miniaturization, automation and ... a powerful tool with many applications ... These applications range from gene expression ...
... This reagent is formulated specifically for ... consistently high levels of activity for both ... storage at final dilution. This product ... stability providing the customer a longer shelf ...
... easy-to-use kits for arraying proteins of ... common lab equipment. DiscoverLight Protein Array ... your protein, cell lysate or antibody ... kits include specially designed nitrocellulose membranes ...
... formulated specifically for Alkaline Phosphatase conjugates. ... activity for both the enzyme and the ... This product has been chemically engineered ... a longer shelf life, resistance to various ...
Biology Products: